The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.
May 16th 2024
This cross-sectional analysis demonstrates the impact that comorbidities in multiple sclerosis (MS) have on sleep quality in affected patients.
Strategies for the Management and Treatment of ALS: The Value of Early Diagnosis and Clinical Intervention
3.0 Credits / Neurology
View More
Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis
June 27, 2024 | 1:00 PM & 7:00 PM ET
View More
Leveraging Managed Care to Optimize Best Practices in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1.0 Credit / Neurology
View More
Improving Outcomes and Quality of Care in Spinal Muscular Atrophy: Updates in Treatment Advances
2.0 Credits / Neurology
View More
New and Emerging Treatment Strategies for Myasthenia Gravis: The Role of the Specialty Pharmacist
1.0 Credit / Neurology
View More
Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden
1.5 Credits / Neurology
View More
Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care
1.5 Credits / Neurology
View More
Identifying Biomarkers to Predict Disease Severity, Progression, and Cognitive Impairment in MS
June 6th 2019Two abstracts presented at the 33rd Annual Meeting of the Consortium of Multiple Sclerosis Centers analyzed biomarkers to predict progression, disease severity, and cognitive impairment in multiple sclerosis (MS).
Read More
Ozanimod Improves Cognition, Increases Rate of No Evidence of Disease Activity in MS
June 1st 2019Long-term use of ozanimod may be associated with improved cognitive speed and higher rates of no evidence of disease activity among patients with relapsing multiple sclerosis (MS), according to 2 new abstracts presented at the 33rd Annual Meeting of the Consortium of Multiple Sclerosis Centers.
Read More
Study Highlights Efficacy of Ozanimod in Relapsing Multiple Sclerosis
May 30th 2019Patients who switched from ozanimod HCI 0.5 mg or interferon β-1a to ozanimod HCI 1.0 mg in an open-label extension study experienced sustained reduction in their annualized relapse rate. Patients who continued on with the 1.0 mg dose also experienced a sustained reduction.
Read More
Researchers Identify Potential Cause of Relapses in MS
May 18th 2019According to new research published in PNAS, researchers have determined that a molecule that helps blood clot may also play a role in multiple sclerosis (MS) relapses, in addition to discovering a new way of studying the disease in mice that more closely resembles the human form.
Read More
Ozanimod Reduces Gray Matter Volume Loss in Patients With MS
May 13th 2019Adults with relapsing multiple sclerosis (MS) who are treated with ozanimod have less gray matter volume loss than patients treated with interferon, according to a post hoc analysis from the phase 3 RADIANCE Part B trial. The research was presented at the 2019 American Academy of Neurology Annual Meeting.
Read More
MS Diagnosis Alone May Not Deem Pregnancy "High Risk," Study Finds
May 10th 2019During an oral presentation of abstracts at the American Academy of Neurology’s 2019 Annual Meeting in Philadelphia, Pennsylvania, held May 4-10, researchers presented findings that suggest that while pregnant women with multiple sclerosis (MS) are often viewed as high-risk by their physician, pregnancy did not seem to increase the risk of adverse obstetrical outcomes for patients nor their babies.
Read More
Dr Rhonda Voskuhl Explains How Understanding Sex Differences Can Lead to MS Treatments
May 8th 2019Research has shown that females are more susceptible to developing multiple sclerosis (MS) than males, but males have worse disease progression, and studying those sex differences can help lead to new treatments, said Rhonda Voskuhl, MD, Jack H. Skirball chair of MS research, director of the MS program, and professor of neurology at the University of California, Los Angeles (UCLA).
Watch
Claims Data Can Provide New Insight Into the Condition of Patients With MS
May 3rd 2019Analyses of real-world data have broadened the understanding of multiple sclerosis (MS) and provided a snapshot into patient conditions and healthcare costs in the years leading up to and the years after an MS diagnosis, explained Bruce Pyenson, FSA, MAAA, Principal, Consulting Actuary, Milliman, Inc, during a session highlighting findings of a recent Milliman white paper at Asembia’s 15th annual Specialty Pharmacy Summit, held April 29 to May 2 in Las Vegas, Nevada.
Read More
Study Finds Increased Out-of-Pocket Costs for Neurologic Treatments
May 2nd 2019In a study to be presented at the American Academy of Neurology’s annual meeting next week, May 4-10, 2019, in Philadelphia, Pennsylvania, researchers found that the out-of-pocket costs for neurologic medications have increased significantly over the past 12 years, particularly for those enrolled in high-deductible health plans.
Read More
Higher Strength MRI Offers Greater Detection of Cortical Lesions in MS
April 26th 2019Cortical lesions play a major role in the progression of multiple sclerosis (MS). A recent study looked to longitudinally characterize the development and evolution of cortical lesions in MS across the cortical width, as well as their relationship with white matter lesion accrual.
Read More
Evaluating Use and Impact of High-Efficacy Multiple Sclerosis Treatments
April 24th 2019Currently, there is no universally accepted treatment standard for multiple sclerosis (MS), but 2 abstracts being presented at the American Academy of Neurology annual meeting evaluated the use and impact of highly effective therapies.
Read More
Dr Rhonda Voskuhl Outlines the Importance of Studying Sex Differences in MS
April 20th 2019Sex differences in multiple sclerosis (MS) has been known for some time, and studying these differences benefit both sexes, explained Rhonda Voskuhl, MD, Jack H. Skirball chair of MS research, director of the MS program, and professor of neurology at the University of California, Los Angeles.
Watch